Company intelligence / Profile preview

Albris Pharma

Zurich, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Albris Pharma is a Swiss clinical-stage biopharmaceutical company focused on developing treatments for rare and orphan diseases with high unmet medical needs. The company's lead program, AP-101, is a topical formulation of diacerein currently being evaluated for the treatment of Epidermolysis Bullosa Simplex (EBS). By targeting the pro-inflammatory cytokine Interleukin-1 beta, Albris aims to provide a disease-modifying therapy for patients suffering from this debilitating genetic skin condition. The company is led by an experienced management team with extensive expertise in the dermatology and orphan drug sectors.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Albris Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albris Pharma.

Explore the full profile